1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Phase III Results Could Boost Pfizer Revenue Ahead Of Xtandi’s Exclusivity Loss

 
• By Alaric DeArment

Pfizer and Astellas announced positive topline Phase III results in non-metastatic prostate cancer for Xtandi, one of the top-selling drugs in Pfizer’s portfolio set to lose patent exclusivity this decade.

Pfizer may be able to soften the blow of an impendent exclusivity loss for Xtandi • Source: Shutterstock

Pfizer Inc. may be able to soften the blow of the impending loss of exclusivity for Xtandi (enzalutamide) by boosting revenue from the drug ahead of its patent expiration. That is because the company and its partner Astellas Pharma, Inc. reported topline Phase III results that may be able to broaden the scope of prostate cancer patients eligible for treatment.

Without disclosing full data, Pfizer and Astellas announced positive results on 16 March from the EMBARK trial of Xtandi in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC), also known as non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from R&D

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.